reason report
upgrad mp due improv fundament pt
bottom line upgrad teva under-perform market
perform due improv busi fundament well
improv multipl overal gener sector compani
fundament improv meaning last month
manag defend copaxon franchis maintain brand
share despit two gener entrant continu grow austedo
obtain time approv ajovi fremanezumab continu
ration cost faster plan put teva posit
pay debt addit stabl
price environ improv indic fda approv
complex product gener epipen start see
valuat multipl gener peer group improv one
year ago current lower ep estim
consensu appropri reflect
ou fx headwind growth rate partial off-set
slightli lower oper expens estim chang
estim result neg impact howev revis
valuat reflect higher gx peer group ev/ebitda
multipl use weight averag multipl
teva vs previous contribut pt
final revis net debt compon valuat
reflect expect debt paydown manag
guidanc vs previous
complet contribut pt overal
chang result increas pt previous
see balanc risk-reward improv fundament
specialti segment copaxon reflect feedback
medacorp specialist analysi believ teva
good posit beat target us sale lp
estim appear despit op aggress
price strategi switch gener remain slow due major
prescript instruct physician dispens written
continu aggress rebat teva hesit physician
payer switch exist well-control patient gener
ajovi recent approv put teva second calcitonin gene-
relat peptid cgrp race even though mp
first mover advantag teva compani
autoinjector market estim cgrp
market ramp quickli patient cgrp
teva aggress drive share payer contract
assum gross-to-net gain mid-teen market
share result sale year physician feedback
austedo continu indic physician prefer titrat
flexibl allow continu gain traction ramp nice
growth come mostli
tardiv dyskinesia indic
ev/ebitda multipl
ebitda
net debt total capit
gener unless otherwis note
compani inform leerink partner llc research
revenu adjust non-gaap ep present
pleas refer page import disclosur price chart analyst certif
proair teva continu benefit gener fall
short fda approv point see gener entri come
outlook us gener improv slightli continu
expect us gener segment sale declin y/i
would expect declin temper see
improv overal price trend potenti contribut
new product launch launch gx ciali day exclus
provid teva notabl sale contribut
includ total new product launch
includ product gx epipen launch expect later
gx restasi approv expect late ag
proair assum gx forteo assum approv
gx nuvar assum approv gx vesicar settlement
see leverag continu declin see go
teva remain track execut
cost save target manag commit
debt pay project continu declin leverag ratio
longer term
manag point leverag
time-frame believ achiev goal given current
state busi
could make us construct teva faster-than-
expect ramp ajovi austedo addit new gener product
approv particularli complex type similar epipen better
visibl sustain copaxon proair revenu cost
save beyond manag guidanc total
indic total cost
bodi note includ market model ajovi
austedo copaxon proair also includ latest
attribut neutral outlook due five main factor brand copaxon continu
hold volum share austedo track sale year gx proair
delay yet potenti earliest ajovi approv time
septemb cost trend level even manag initi guidanc
still see risk consensu number believ matter
time meaning gener competit hit copaxon proair still struggl see
growth us gener believ manag done good job stabil busi
build block place busi grow start rate teva market
perform price target
figur chang model
lp estim note number except ep
total cost summat cog sg
price target base ebitda ev/ebitda multipl
line higher gx peer group ev/ebitda multipl
continu delay new gener opportun slower-than-anticip ramp ajovi could result
teva trade lower price target addit delay gener competit copaxon
proair along faster growth austedo could result teva trade price target
sale
patient suffer migrain
proport diagnos activ
mild
moder
sever
chronic
number activ
penetr cgrp sub popul
use cgrp mab across sub-popul
migrain pt cgrp
market share inject
gross net
treatment per patient per period
compani report leerink partner research
sale
us patient antipsychot
us patient atyp
us patient typic
td patient us
candid inhibitor survey
moder sever td pt candiat
treat vmat inhibitor survey
td patient inhibitor
austedo share use
valbenazin share use
tetrabenazin share use
overal td patient austedo
pt austedo
gross net adjust
compani report leerink partner research
sale
hd patient us
overal hd patient tetrabenazin
pt tetrabenazin
overal hd patient austedo
pt austedo
gross net adjust
compani report leerink partner research
sale
tourett pediatr patient us
tourett adult patient us
candid pharmacotherapi
candid pharmacotherapi
treat ingrezza
treat austedo
pt austedo
total ts market austedo
probabl success
compani report leerink partner research
sale
sale
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
number except per share data
number except per share data
disclos ftf notabl pipelin
viagra sildenafil dec settlement exclus
viread tenofovir dec settlemnet exclus
reyataz atazanavir dec settlement exclus
byetta exenatid inj oct settlement exclus
effient prasugrel launch patent expiri oct
butran launch sept patent expir
nuvar appeal state patent valid pend approv
renvela assum approv pend approv
acanya jul settlement exclus approv
pazeo settlement may pend approv
exjad assum month patent expiri approv
moviprep settlement sept pend approv
solodyn feb feb launch specif strength approv
uceri assum patent invalid hold oct launch pend approv
letairi undisclos settlement assum month last patent pend approv
levitra assum month patent tent approv
restasi patent invalid await appeal assum launch pend approv
number except per share data
noxafil drt assum compound patent expir jul hold pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
